<DOC>
	<DOCNO>NCT01566565</DOCNO>
	<brief_summary>This Phase I , three period , two sequence , open-label , randomize , crossover study , primary objective test safety tolerability combine oral dos theophylline bambuterol healthy human subject . The secondary objective ass pharmacokinetic profile theophylline bambuterol administer alone combination . It hypothesize combination drug generally safe , drug interaction observe .</brief_summary>
	<brief_title>The Safety Evaluation Drug Combinations Against High Altitude Pulmonary Hypertension</brief_title>
	<detailed_description>This Phase I , three period , two sequence , single-center , open-label , randomize , crossover study design . Periods I II consist oral administration either single dose theophylline bambuterol alone , follow 7 day wash interval . Subsequently , Period III consist simultaneous administration drug . All subject confine Oslo University Hospital Research Unit throughout treatment period [ Study Day 1 , 7 14 ] . A sufficient number healthy adult subject consent order enroll 20 complete 16 subject complete three period . Replacement subject permit , necessary . Qualified subject randomize one two sequence consist three Periods indicate : -- -- -- -- -- -- -Period 1 -- -- -Period 2 -- -- -Period 3 Sequence A : Treatment 1 Treatment 2 Treatment 3 Sequence B : Treatment 2 Treatment 1 Treatment 3 TREATMENTS : Treatment 1 : Theophylline 300 mg . Treatment 2 : Bambuterol 20 mg . Treatment 3 : Theophylline 300 mg plus Bambuterol 20 mg. After completion treatment period , subject proceed next period provide Stopping Rules criterion meet</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Altitude Sickness</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<mesh_term>Bambuterol</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<criteria>Inclusion criterion : 1 . Subjects must give write informed consent participation study prior screen . Consent document subject 's dated signature 2 . Subjects must healthy nonsmoking adult male female volunteer age 18 40 year , BMI 1830 kg/m2 weigh least 68 kg . Subjects health status determine medical history , physical examination , vital sign , electrocardiogram , blood chemistry , hematology , urinalysis perform screen . 3 . Subjects must willing fast minimum 8 hour prior screen . 4 . Subjects must willing abstain alcohol xanthinecontaining food beverage ( example coffee , tea , cola ) 48 hour time admission clinical research inpatient unit last PK sample drug give day 1 , 7 14 drawn 24 hour . 5 . Subjects must willing remain clinical research unit continuously inpatient portion study admission discharge . 6 . Women nonchildbearing potential , must : 1 . Surgically sterile ( removal ovary and/ uterus least 12 month prior dose ) 2 . Naturally postmenopausal ( spontaneous cessation menses ) least 24 consecutive month prior dose Day 1 , FSH level screen ≥ 40 mIU/mL . 7 . Women childbearing potential must negative serum pregnancy test within 48 hour receive study drug must agree avoid pregnancy study one month last dose study drug . 8 . Female subject childbearing potential must agree avoid pregnancy study three month last dose study drug . 9 . Subjects must agree donate blood , plasma , platelet , blood component study 4 week last dose . 10 . Male subject must agree donate sperm study 12 week last dose . Exclusion criterion Individuals meet ANY ONE follow criterion exclude study : 1 . Subjects laboratory result outside normal range , consider clinically significant Investigator . In addition , subject must normal hematocrit hemoglobin concentration ≥ 36 % ≥ 12.0 g/dL , respectively plasma potassium concentration least 3.9 mmol/l . 2 . A mental capacity limit extent subject provide legal consent understand information regard side effect study drug . 3 . Currently abuse drug alcohol history drug alcohol abuse within past two year . 4 . Unwillingness lack ability comply protocol , reside inpatient unit required time period , cooperate fully Principle Investigator site personnel . 5 . Use follow : 1 . Any concomitant medication include oral contraceptive hormone . Subjects receive prescribed nonprescribed ( overthecounter [ OTC ] ) systemic medication , topical medication , herbal supplement within 14 day Day 1 . St. John 's Wort ( hypericin ) must take least 30 day prior Period 1 , Day 1 . 2 . Any drug , food substance know strong inhibitor strong inducer CYP enzyme ( also know cytochrome P450 enzyme ) ; especially CYP 1A2 , Pgp within 30 day prior Period 1 , Day 1 . 6 . Clinically significant ECG abnormality opinion Investigator . 7 . Vital sign clinically significant laboratory value screen visit opinion Investigator would make subject inappropriate candidate study . 8 . Has take investigational drug 30 day prior screen visit currently participate another investigational clinical trial . 9 . Made significant donation ( include plasma ) significant loss blood within 30 90 day prior Period 1 , Day 1 . 10 . History manifestation clinically significant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychological , pulmonary , metabolic , endocrine , hematologic medical disorder . 11 . Subjects carrier Hepatitis B surface antigen ( HbsAg ) , Hepatitis C antibody , HIV antibody . 12 . Serious mental physical illness within past year . 13 . Male subject consume 28 unit alcohol per week female subject consume 21 unit alcohol per week ( one unit alcohol equal 250 mL beer , 100 mL medium glass wine , 25 mL spirit ) subject significant history alcoholism drug/ chemical abuse within last 2 year . 14 . Failure agree abstain alcohol , cola , tea , coffee , chocolate caffeinated drink/ food 2 day dose throughout confinement . 15 . Positive result screen test drug abuse , cotinine alcohol screen predose assessment checkin . 16 . Subjects use tobacco product nicotinecontaining product ( include smoke cessation aid , gum patch ) within 12 month prior Period 1 , Day 1 . 17 . Women childbearing potential pregnant ( base test result ) breast feed . 18 . Subjects history hypersensitivity idiosyncratic reaction product administer study . 19 . Subjects , opinion Investigator , participate study . 20 . Subjects history unexplained syncope ; i.e. , autonomic dysfunction . 21 . Subjects history hypotension , include orthostatic hypotension . 22 . Lack ability understand verbal and/ write Norwegian . 23 . History severe hypersensitivity allergic reaction study medication . 24 . Failure agree abstain grapefruit grapefruit juice well oranges orange juice 10 day first dose throughout study . 25 . History clinically significant illness within 4 week prior Day 1 . 26 . Receipt transfusion blood product within 90 day prior Period 1 , Day 1 . 27 . History participation another investigational study participate investigational study within past 30 day prior Period 1 , Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>